Senaparib is an investigational new drug that is being evaluated to treat ovarian cancer.[1] It is a PARP inhibitor.[2]

Senaparib
Clinical data
Other namesIMP-4297
Legal status
Legal status
  • Invesigational
Identifiers
  • 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC24H20F2N6O3
Molar mass478.460 g·mol−1
3D model (JSmol)
  • C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O)F
  • InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35)
  • Key:VBTUJTGLLREMNW-UHFFFAOYSA-N

References

edit
  1. ^ "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE (June 2024). "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics: OF1–OF9. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409.